ArticleJournal of virology1998
Efficient infection mediated by viral receptors incorporated into retroviral particles.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Defining the molecular interaction between influenza hemagglutinin and MHC-II.bioRxiv : the preprint server for biology · 2026Article
- Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy.Antibodies (Basel, Switzerland) · 2024Article
- Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point.iScience · 2022Article
- Improving antibody drug development using bionanotechnology.Current opinion in biotechnology · 2022Review
- Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors.Journal of virology · 2013Article
- Article
- Activity-induced remodeling of olfactory bulb microcircuits revealed by monosynaptic tracing.PloS one · 2011Article
- Cell entry of enveloped viruses.Advances in genetics · 2011Review
- Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles.Journal of virology · 2008Article
- Article
- Molecular engineering of viral gene delivery vehicles.Annual review of biomedical engineering · 2008Review
- Tagging retrovirus vectors with a metal binding peptide and one-step purification by immobilized metal affinity chromatography.Journal of virology · 2004Article
- Membrane transplantation to correct integral membrane protein defects.Journal of molecular medicine (Berlin, Germany) · 2003Article
- Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope.Journal of virology · 2001Article
- Properties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles.Journal of virology · 2001Article
- A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Soluble receptor-induced retroviral infection of receptor-deficient cells.Journal of virology · 2000Article
- Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titre.Gene therapy · 2000Article
- Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping.Journal of virology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many host cell surface proteins, including viral receptors, are incorporated into enveloped viruses. To address the functional significance of these host proteins, murine leukemia viruses containing the cellular receptors for Rous sarcoma virus (Tva) or ecotropic murine leukemia virus (MCAT-1) were produced. These receptor-pseudotyped viruses efficiently infect cells expressing the cognate viral envelope glycoproteins, with titers of up to 10(5) infectious units per milliliter for the Tva pseudotypes. Receptor and viral glycoprotein specificity and functional requirements are maintained, suggesting that receptor pseudotype infection recapitulates events of normal viral entry. The ability of the Tva and MCAT-1 pseudotypes to infect cells efficiently suggests that, in contrast to human immunodeficiency virus type 1 entry, neither of these retroviral receptors requires a coreceptor for membrane fusion. In addition, the ability of receptor pseudotypes to target infected cells suggests that they may be useful therapeutic reagents for directing infection of viral vectors. Receptor-pseudotyped viruses may be useful for identifying new viral receptors or for defining functional requirements of known receptors. Moreover, this work suggests that the production of receptor pseudotypes in vivo could provide a mechanism for expanded viral tropism with potential effects on the pathogenesis and evolution of the virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.